Peptide synthesis company completes new funding round...
Press Release: 10th January 2008
UK-based peptide synthesis technology company, Activotec
(www.activotec.com), has just completed a significant funding round to
enable it to further accelerate the growth of its business.
Activotec is a peptide synthesis company providing innovative custom peptide
synthesis services, peptide synthesizers and therapeutic peptide development
for chemical research and development. Founded in 2002, as a spin out from
the University of Southampton, Activotec has built a highly skilled team of
research and production scientists, product specialists and service
engineer's with unique experience in serving the peptide community.
Reflecting the solid growth achieved by the company over the last few years
the new funding money was raised quickly through a syndicate comprised of
Activotec's existing shareholders.
Activotec chief executive, Chris Littlewood, commented: "The funds will be
invested in expanding our research and development as well as new personnel
and premises. This will assist us in our dual strategy of accelerating our
peptide synthesiser development and sales as well as leveraging our
innovative peptide technology through collaborative projects with
biotechnology and pharmaceutical partners to develop new peptide
therapeutics.
About Activotec
Activotec is a developer and manufacturer of automated peptide synthesizers.
The Activo-P11 peptide synthesizer is an easy to use and affordable
instrument for synthesis of very high quality peptides on a scale from 0.05
to 1.0 mmole. For many years - Activotec's custom peptide facility has been
providing customers around the world with the highest-quality peptides at
competitive prices. Operating out of a modern peptide synthesis facility in
the UK the company is able to provide with fast delivery times milligram
(mg) to multiple grams of peptides at all required purity levels and with
any modifications required. Particular expertise focuses on
difficult-to-synthesise sequences, non-natural modifications, and the design
and synthesis of highly effective peptide therapeutics. Activotec also has
an extensive R&D programme based on the modification and production of
peptides and proteins for therapeutic use. The Company has filed a number of
patent applications based on various synthesis techniques. Further patents
have been filed relating to the development of novel peptide-based products
for the treatment of cancer, HIV and diabetes.
If you would like further information please contact
chris.littlewood@activotec.com or call Activotec on +44 1223 26008.
| 
